Brought to you by 
Nippon Shoji Kaisha to develop Applied Microbiology's nisin
13 Jul 1999
Executive Summary
Japan's Nippon Shoji Kaisha will exclusively develop Applied Microbiology Inc.'s antimicrobial peptide nisin (for treatment of hospital-acquired infections and colon infections) in Japan, certain Asian countries, Australia and New Zealand.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nippon Shoji Kaisha to develop Applied Microbiology's nisin
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice